Ivergalen

Ivermectin, the active ingredient in Ivergalen, is an antiparasitic (macrocyclic lactone) presented as an oral tablet for oral use. It is employed to treat a range of parasitic infections, including river blindness, strongyloidiasis, scabies, lice and various intestinal helminths, primarily in adult and pediatric patients as directed by a healthcare professional.

GNH USA supplies Ivergalen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Ivergalen is an antiparasitic medication used to manage infections caused by nematodes and ectoparasites. - Onchocerciasis (river blindness): reduces microfilarial load and helps prevent ocular and skin disease. - Strongyloidiasis: eliminates intestinal larvae and prevents disseminated infection. - Scabies: eradicates Sarcoptes scabiei mites, relieving itching and skin lesions. - Lice infestations: kills Pediculus humanus capitis and Pediculus humanus corporis, controlling spread. - Other intestinal helminth infections: clears a variety of nematode species from the gastrointestinal tract.

Ivergalen may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Dizziness: occasional light‑headedness. - Abdominal pain: cramping or discomfort. - Diarrhea: loose stools. - Pruritus: itching of the skin. - Headache: mild tension‑type pain.

Serious or Rare Side Effects: - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hepatotoxicity: elevated liver enzymes or jaundice. - Neurologic effects: seizures, ataxia or altered consciousness. - Anaphylaxis: acute allergic response requiring emergency care. - Vision changes: blurred vision or optic neuritis. - Cardiac arrhythmias: rare conduction abnormalities.

Before prescribing Ivergalen, clinicians should consider several safety measures. - Assess contraindications: avoid use in patients with known hypersensitivity to ivermectin. - Monitor liver function: evaluate hepatic status in patients with pre‑existing liver disease. - Caution with Loa loa infection: high microfilarial loads can precipitate severe reactions. - Review concomitant medications: check for drugs that affect CYP3A4 or P‑glycoprotein pathways. - Educate patients: advise on potential side effects and the importance of adherence. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Ivergalen can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase ivermectin plasma levels. - P‑glycoprotein inhibitors (e.g., verapamil, quinidine): can raise systemic exposure. - Concurrent neurotoxic agents (e.g., albendazole in high doses): risk of additive neurologic effects.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Macrolide antibiotics (e.g., erythromycin): modest increase in ivermectin concentrations. - Statins metabolized by CYP3A4: observe for muscle toxicity.